Revelation Biosciences 5/8/2025 Earnings Report

Revelation Biosciences EPS Results

• Actual EPS: -$6.33
• Consensus EPS: -$20.64
• Beat/Miss: Beat by +$14.31
• One Year Ago EPS: N/A

Revelation Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Revelation Biosciences Announcement Details

• Date: 5/8/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Revelation Biosciences (NASDAQ:REVB) (NASDAQ: REVB) is a clinical-stage biotechnology company specializing in the development of engineered cellular therapies for oncology. The company’s proprietary platform employs gene-editing techniques to produce macrophages with enhanced tumor-infiltrating and immune-activating capabilities. By leveraging both innate and adaptive immune mechanisms, Revelation Biosciences aims to overcome the immunosuppressive microenvironment that limits the efficacy of many current cancer treatments.

The company’s lead product candidate is a macrophage-based immunotherapy designed to target and treat multiple solid tumor types. Preclinical studies have demonstrated its ability to remodel the tumor microenvironment, activate T-cell responses and reduce tumor burden in various models. In addition to its core oncology focus, Revelation Biosciences is evaluating broader applications of its macrophage engineering technology in hematological malignancies and other disease areas where immune evasion is a key challenge.

Revelation Biosciences collaborates with academic institutions and contract research organizations across North America and Europe to advance its pipeline. Its multidisciplinary team includes experts in cell biology, immunology and genetic engineering, all working to translate preclinical success into clinical progress. The company is preparing to initiate its first-in-human trial for its lead candidate, marking a significant milestone toward delivering novel immunotherapies to patients with high unmet medical need.